The comparative one-year performance of anti-turmor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

Arthritis Care and Research

Volumn 59, Issue 2, 2008, Pages 234-240

  Heiberg, Marte Schrumpf ^a   Koldingsnes, Wenche ^b   Mikkelsen, Knut ^c   Rødevand, Erik ^d   Kaufmann, Cecilie ^e   Mowinckel, Petter ^a   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c Hospital for Rheumatic Diseases   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e Buskerud Central Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NORWAY; PHASE 4 CLINICAL TRIAL; PHYSICAL CAPACITY; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39449132386     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23333     Document Type: Article

References (28)

1. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, et al. ASAS/EUCLAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2009;65:442-52.
2. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
3. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
4. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
5. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
6. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
7. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
8. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
9. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
10. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
11. Pincus T, Marcum SB, Callahan LF, Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
12. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
13. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-8.
14. Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(5 Suppl 39):S188-94.
15. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 30-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
16. Kleinbaum DG. Applied regression analysis and other multivariable methods. Boston: PWS-Kent Publishing Company: 1988.
17. Kvien TK, Mikkelsen K, Nordvag BY. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol 2003;30:1135-7.
18. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004;63 Suppl 2:ii13-7.
19. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999;58 Suppl 1:I82-5.
20. Heiberg MS, Nordvag BY, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
21. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven RV, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2005;54:26-37.
22. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
23. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9.
24. Heiberg MS, Rodevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis 2006;65:1379-83.
25. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
26. De Vries MK, Wolbink GJ, Stapel S, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased clinical response to infliximab in ankylosing spondylitis (AS) is correlated with anti-infliximab formation. Ann Rheum Dis 2007;66:1252-4.
27. Kristensen LE, Geborek P, Nilsson JA, Saxne T, Compagno M, Jacobsson L. Predictors for terminating therapy of etanercept and infliximab in psoriatic arthritis patients [abstract]. Arthritis Rheum 2006;54:S721-2.
28. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.